Idiopathic pulmonary fibrosis, a rare progressive disease characterized by fibrosis in the alveoli of the lungs, has a median survival of 3 to 5 years if left untreated. Inhaled treprostinil slowed ...

United Therapeutics has linked a once-daily drug candidate to a 55% drop in the risk of clinical worsening in a phase 3 trial, setting the company up to seek FDA approval in pulmonary arterial ...

United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically ...

United Therapeutics plans to file for approval of ralinepag as a treatment for pulmonary arterial hypertension (PAH) before the end of the year, after positive results in a phase 3 trial. The drug ...

CEO Martine Rothblatt announced a "category killer product called [Tresmi]"—a proprietary soft mist inhaler formulation of treprostinil, designed to reduce coughing by up to 90% in human studies. "We ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the arteries in your lungs. It happens when these arteries become narrow or blocked, making it harder for blood to flow ...

Findings in The American Journal of Pathology open avenues for development of therapeutic strategies to enhance membrane repair and prevent preterm birth “Preterm birth is a major challenge in ...

We wanted to review whether a group of drugs called prostacyclin analogues help people with pulmonary hypertension. Cochrane researchers collected and analysed all relevant studies to answer this ...

Van Andel Institute scientists and collaborators have discovered a potential treatment target that may re-energize dysfunctional or "exhausted" immune cells in their fight against cancer. The target ...